Omada Health Inc. Common Stock (OMDA) fair value

ACCE thesis

Omada Health sells a digital care program for chronic conditions, mainly type 2 diabetes, hypertension and obesity, that pairs an app and connected devices with care coaches and clinicians, and sells it to employers and health plans. Its moat is still forming: the program's clinical outcomes data and payer contracts are what make it hard to displace, and at 43.1% revenue growth with a 68.2% gross margin the unit economics are clearly working at the top line. The growth story turns on whether operating leverage arrives, since the 4.0% operating margin is thin for a business priced at 137.0x forward earnings, so the next few reporting periods on margin expansion and member growth will matter more than any single product announcement. What makes it worth a look now is the gap between valuation and profitability: a 1.8% return on equity and a 77.8x trailing P/E mean the market is paying for growth that has not yet reached the bottom line. The score of 51/100 and the absence of any index membership suggest the name sits outside most screens, which is a reason to check the margin trajectory directly rather than rely on the headline growth rate.